Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (NASDAQ: TOI) generates a steady flow of news as it pursues its strategy in value-based community oncology care. Founded in 2007, the company describes itself as one of the largest value-based oncology groups in the United States, with over 180 employed and affiliate clinicians and more than 100 clinics and affiliate locations of care across five states. News about TOI often highlights how it combines specialized cancer care with value-based payment models and community-based delivery.
Investors and observers following TOI news can expect updates on financial performance, guidance, and outlook, including revenue mix across patient services, dispensary, and capitation arrangements. The company regularly issues press releases on quarterly results, non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow, and changes to its financial guidance. These items are often accompanied by management commentary on operational trends in areas like pharmacy, dispensary, and delegated contracts.
TOI’s news flow also covers clinical and operational initiatives. Examples include participation in CMS programs such as the Enhancing Oncology Model, where the company has reported Medicare savings and quality scores, as well as the launch of centers of excellence, such as a Lung Cancer Center of Excellence in Florida. Announcements may describe programs like its High Value Cancer Care initiative, 24/7 symptom management support, and efforts to reduce avoidable emergency department visits and admissions.
Another recurring theme in TOI news is technology and leadership. The company has reported partnerships to co-develop AI-enabled administrative automation, and it has announced leadership promotions and board changes that relate to technology strategy, people operations, and financial oversight. For readers tracking TOI, this news page offers a way to follow developments in value-based oncology care, operational efficiency initiatives, and governance updates over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
The Oncology Institute (TOI), a leading value-based oncology group in the U.S., is set to announce its Q1 2023 financial results on May 10, 2023, after market close. A conference call will follow at 5:00 p.m. ET, accessible via phone or webcast. Founded in 2007, TOI provides specialized cancer care to approximately 1.7 million patients through its network of over 60 clinics and more than 100 clinicians. With a focus on evidence-based treatments and clinical trials, TOI is committed to enhancing cancer care delivery. For more details, visit TOI's investor relations webpage.
The Oncology Institute (NASDAQ: TOI) reported an adjustment to its financials for Q4 and FY 2022, resulting in a $1.5 million increase in net loss for Q4 and a $1.5 million decrease in net income for the full year. In Q4, revenue rose 36.6% to $71 million, while gross profit increased 87.6% to $16 million. The company ended 2022 with $132 million in cash. Despite facing challenges, TOI exceeded revised revenue and EBITDA guidance. For 2023, the company forecasts revenue of $290-$320 million, up 15%-27%, and anticipates a net loss of $(25) to $(28) million, while projecting growth in value-based lives to 1.75-2 million.
The Oncology Institute reported a 36.6% revenue increase to $71 million for Q4 2022, with a net loss of $9.5 million, improved from a loss of $10.2 million in Q4 2021. Full-year revenue reached $252 million, up 24.4%, with a net income of $1.7 million, a significant increase from the prior year. The company ended 2022 with $132 million in cash and completed six practice acquisitions, expanding its market count from 10 to 15. They anticipate 2023 revenue guidance between $290 million and $320 million, reflecting 15% to 27% growth over 2022. Adjusted EBITDA for 2023 is projected at $(25) to $(28) million.
The Oncology Institute (NASDAQ: TOI) announced participation in key investor conferences in March 2023. Senior management will present at:
- Cowen 43rd Annual Healthcare Conference on March 7 at 2:50 PM ET in Boston, featuring Daniel Virnich, M.D., MBA, President.
- Oppenheimer 33rd Annual Healthcare Conference on March 13 at 10:00 AM ET, virtually, featuring Brad Hively, CEO.
- Jefferies Value-Based Healthcare Summit on March 13 at 1:15 PM ET in Miami, also featuring Brad Hively, CEO.
Webcasts of the presentations will be available for interested investors on the company’s website.
The Oncology Institute (TOI) will release its Q4 & full year 2022 financial results after market close on March 9, 2023. A conference call will follow at 5:00 p.m. ET. Investors can participate via phone or by accessing a webcast through the Investor Relations section of TOI's website. TOI, founded in 2007, specializes in value-based cancer care, servicing approximately 1.7 million patients with over 90 clinicians and more than 700 teammates across 50+ locations. The company is focused on advancing oncology with evidence-based care and innovative delivery models.